Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study

BACKGROUND: The most common type of primary liver cancer is hepatocellular carcinoma (HCC), and hepatitis B virus (HBV)-related HCC accounts for many HCC cases and has a high mortality rate. The goal of our study was to investigate the efficacy and safety of lenvatinib plus sintilimab therapy in rea...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Lei, Chang, Niajia, Shi, Lei, Li, Fengyi, Meng, Fanglin, Xie, Xiaohui, Xu, Zhe, Wang, Fusheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189019/
https://www.ncbi.nlm.nih.gov/pubmed/35706954
http://dx.doi.org/10.1016/j.heliyon.2022.e09538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189019/
https://www.ncbi.nlm.nih.gov/pubmed/35706954
http://dx.doi.org/10.1016/j.heliyon.2022.e09538

Ejemplares similares